[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fjDB_V73bkIXKcvrcGlPJ4YoA0ReukkWgWnFQ4S6Iosk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":43,"rows":50},"Abbott Medical Devices",[4],536,false,65,18,332303,1,525,[14,17,20,23,26,29,32,34],{"name":15,"count":16},"Heart Failure",85,{"name":18,"count":19},"Coronary Artery Disease",72,{"name":21,"count":22},"Atrial Fibrillation",34,{"name":24,"count":25},"Coronary Disease",28,{"name":27,"count":28},"Bradycardia",25,{"name":30,"count":31},"Coronary Artery Stenosis",23,{"name":33,"count":31},"Coronary Restenosis",{"name":35,"count":36},"Myocardial Ischemia",20,[38],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT04226547","Amplatzer Amulet LAAO vs. NOAC","2029-01","Non-Vitamin K Oral Antagonists",[44,45,46,47,48,49],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[51,76,104,129,147,174,231,256,280,306],{"intervention":42,"totalTrials":11,"cells":52},{"EARLY_PHASE1":53,"PHASE1":56,"PHASE2":58,"PHASE3":60,"PHASE4":62,"NA":64},{"trials":54,"activeCount":55},[],0,{"trials":57,"activeCount":55},[],{"trials":59,"activeCount":55},[],{"trials":61,"activeCount":55},[],{"trials":63,"activeCount":55},[],{"trials":65,"activeCount":11,"soonestReadout":41},[66],{"nctId":39,"briefTitle":40,"status":67,"phases":68,"primaryCompletion":41,"completion":69,"start":70,"enrollment":71,"conditions":72,"interventions":75},"ACTIVE_NOT_RECRUITING",[49],"2031-04","2020-07-07",2650,[21,73,74],"Stroke","Bleeding",[42],{"intervention":77,"totalTrials":11,"cells":78},"clopidogrel + aspirin OR prasugrel + aspirin",{"EARLY_PHASE1":79,"PHASE1":81,"PHASE2":83,"PHASE3":85,"PHASE4":87,"NA":102},{"trials":80,"activeCount":55},[],{"trials":82,"activeCount":55},[],{"trials":84,"activeCount":55},[],{"trials":86,"activeCount":55},[],{"trials":88,"activeCount":55},[89],{"nctId":90,"briefTitle":91,"status":92,"phases":93,"primaryCompletion":94,"completion":95,"start":96,"enrollment":97,"conditions":98,"interventions":101},"NCT01106534","XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort","COMPLETED",[48],"2015-02","2015-07","2009-08",870,[99,100,35,30,24,18,33],"Chronic Total Occlusion of Coronary Artery","Vascular Disease",[77],{"trials":103,"activeCount":55},[],{"intervention":105,"totalTrials":11,"cells":106},"Warfarin",{"EARLY_PHASE1":107,"PHASE1":109,"PHASE2":111,"PHASE3":113,"PHASE4":115,"NA":127},{"trials":108,"activeCount":55},[],{"trials":110,"activeCount":55},[],{"trials":112,"activeCount":55},[],{"trials":114,"activeCount":55},[],{"trials":116,"activeCount":55},[117],{"nctId":118,"briefTitle":119,"status":92,"phases":120,"primaryCompletion":121,"completion":122,"start":123,"enrollment":19,"conditions":124,"interventions":125},"NCT02836652","Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy",[48],"2019-02-21","2019-07-18","2016-11",[15],[105,126],"acetylsalicylic acid (ASA) therapy",{"trials":128,"activeCount":55},[],{"intervention":126,"totalTrials":11,"cells":130},{"EARLY_PHASE1":131,"PHASE1":133,"PHASE2":135,"PHASE3":137,"PHASE4":139,"NA":145},{"trials":132,"activeCount":55},[],{"trials":134,"activeCount":55},[],{"trials":136,"activeCount":55},[],{"trials":138,"activeCount":55},[],{"trials":140,"activeCount":55},[141],{"nctId":118,"briefTitle":119,"status":92,"phases":142,"primaryCompletion":121,"completion":122,"start":123,"enrollment":19,"conditions":143,"interventions":144},[48],[15],[105,126],{"trials":146,"activeCount":55},[],{"intervention":148,"totalTrials":11,"cells":149},"Medical management\u002Fcurrent medications per standard of care by personal physician.",{"EARLY_PHASE1":150,"PHASE1":152,"PHASE2":154,"PHASE3":156,"PHASE4":170,"NA":172},{"trials":151,"activeCount":55},[],{"trials":153,"activeCount":55},[],{"trials":155,"activeCount":55},[],{"trials":157,"activeCount":55},[158],{"nctId":159,"briefTitle":160,"status":161,"phases":162,"primaryCompletion":163,"completion":163,"start":164,"enrollment":165,"conditions":166,"interventions":169},"NCT00267371","ESCAPE Migraine Trial","TERMINATED",[47],"2012-03","2005-11",168,[167,168],"Migraine Disorders","Heart Septal Defects, Atrial",[148],{"trials":171,"activeCount":55},[],{"trials":173,"activeCount":55},[],{"intervention":175,"totalTrials":176,"cells":177},"DAPT",3,{"EARLY_PHASE1":178,"PHASE1":180,"PHASE2":182,"PHASE3":184,"PHASE4":186,"NA":188},{"trials":179,"activeCount":55},[],{"trials":181,"activeCount":55},[],{"trials":183,"activeCount":55},[],{"trials":185,"activeCount":55},[],{"trials":187,"activeCount":55},[],{"trials":189,"activeCount":55},[190,208,218],{"nctId":191,"briefTitle":192,"status":92,"phases":193,"primaryCompletion":194,"completion":195,"start":196,"enrollment":197,"conditions":198,"interventions":207},"NCT03355742","XIENCE 28 Global Study",[49],"2019-10-24","2020-04-30","2018-02-09",963,[199,200,201,202,203,204,205,206,18],"Bleeding Disorder","Stroke, Ischemic","Stroke Hemorrhagic","Hematological Disease","Thrombocytopenia","Coagulation Disorder","Anemia","Renal Insufficiency",[175],{"nctId":209,"briefTitle":210,"status":92,"phases":211,"primaryCompletion":212,"completion":212,"start":213,"enrollment":214,"conditions":215,"interventions":217},"NCT03218787","XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.",[49],"2020-09-04","2017-07-19",2047,[216],"Coronary Artery Lesions",[175],{"nctId":219,"briefTitle":220,"status":92,"phases":221,"primaryCompletion":222,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":230},"NCT03815175","XIENCE 28 USA Study",[49],"2020-08-14","2021-02-04","2019-02-25",1605,[199,227,228,229,203,204,205,206,18],"Ischemic Stroke","Hemorrhagic Stroke","Hematological Diseases",[175],{"intervention":232,"totalTrials":11,"cells":233},"Amiodarone",{"EARLY_PHASE1":234,"PHASE1":236,"PHASE2":238,"PHASE3":240,"PHASE4":242,"NA":244},{"trials":235,"activeCount":55},[],{"trials":237,"activeCount":55},[],{"trials":239,"activeCount":55},[],{"trials":241,"activeCount":55},[],{"trials":243,"activeCount":55},[],{"trials":245,"activeCount":55},[246],{"nctId":247,"briefTitle":248,"status":161,"phases":249,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":254,"interventions":255},"NCT01276093","Pulmonary Vein Ablation Versus Amiodarone in the Elderly",[49],"2015-12","2016-03","2011-07",59,[21],[232],{"intervention":257,"totalTrials":11,"cells":258},"Aspirin 100mg",{"EARLY_PHASE1":259,"PHASE1":261,"PHASE2":263,"PHASE3":265,"PHASE4":267,"NA":269},{"trials":260,"activeCount":55},[],{"trials":262,"activeCount":55},[],{"trials":264,"activeCount":55},[],{"trials":266,"activeCount":55},[],{"trials":268,"activeCount":55},[],{"trials":270,"activeCount":55},[271],{"nctId":272,"briefTitle":273,"status":92,"phases":274,"primaryCompletion":275,"completion":275,"start":276,"enrollment":277,"conditions":278,"interventions":279},"NCT04069156","The ARIES HeartMate 3 Pump IDE Study",[49],"2023-08-10","2020-07-14",628,[15],[257],{"intervention":281,"totalTrials":11,"cells":282},"Medical Management",{"EARLY_PHASE1":283,"PHASE1":285,"PHASE2":287,"PHASE3":289,"PHASE4":291,"NA":293},{"trials":284,"activeCount":55},[],{"trials":286,"activeCount":55},[],{"trials":288,"activeCount":55},[],{"trials":290,"activeCount":55},[],{"trials":292,"activeCount":55},[],{"trials":294,"activeCount":55},[295],{"nctId":296,"briefTitle":297,"status":92,"phases":298,"primaryCompletion":299,"completion":300,"start":301,"enrollment":302,"conditions":303,"interventions":305},"NCT01288976","ACCESS-Europe A Two-Phase Observational Study of the MitraClip® System in Europe",[],"2012-06","2012-08","2008-10",721,[304],"Mitral Valve (MV) Regurgitation",[281],{"intervention":307,"totalTrials":11,"cells":308},"OMM",{"EARLY_PHASE1":309,"PHASE1":311,"PHASE2":313,"PHASE3":315,"PHASE4":317,"NA":319},{"trials":310,"activeCount":55},[],{"trials":312,"activeCount":55},[],{"trials":314,"activeCount":55},[],{"trials":316,"activeCount":55},[],{"trials":318,"activeCount":55},[],{"trials":320,"activeCount":55},[321],{"nctId":322,"briefTitle":323,"status":92,"phases":324,"primaryCompletion":251,"completion":325,"start":326,"enrollment":327,"conditions":328,"interventions":329},"NCT01452802","Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management",[],"2016-06","2011-10",200,[15],[307]]